Related Experiment Video
Updated: Jun 7, 2025
08:18
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
1.0K
Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative
Hany S M Ali1,2, Ahmed F Hanafy3, Rawan Bafail1
1Department of Pharmaceutics and Pharmaceutical Industries, College of Pharmacy, Taibah University, Madinah, Al-Madinah Al-Munawwarah, Saudi Arabia.
International Journal of Nanomedicine
|November 19, 2024
Summary
Solid self-microemulsifying drug delivery systems (SMEDDS) effectively delivered budesonide (BUD) for ulcerative colitis. These novel BUD-SMEDDS formulations showed superior efficacy in managing colitis in animal models.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Gastroenterology
Background:
- Budesonide (BUD) exhibits poor water solubility and low oral bioavailability, classifying it as a BCS class II medication.
- Ulcerative colitis (UC) requires effective local drug delivery for distal colon management.
Purpose of the Study:
- To develop innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) for enhanced local delivery of budesonide.
- To evaluate the in vitro characteristics and in vivo efficacy of BUD-SMEDDS for treating ulcerative colitis.
Main Methods:
- Self-microemulsifying drug delivery system (SMEDDS) components (Capryol™ 90, Tween 80, Transcutol HP) were optimized using Box-Behnken design.
- Solid rectal formulations were prepared using optimized SMEDDS in Lutrol® bases.
- In vitro characterization and in vivo efficacy in a rat colitis model were assessed.
Main Results:
- Optimized BUD-SMEDDS achieved small globule size (33 ± 2.9 nm), low PDI (0.29 ± 0.03), and rapid self-emulsification time (25 ± 2.5 s).
- Formulations exhibited good physical properties, mucoadhesion, and controlled drug release.
- Significant clinical and histopathological improvements were observed in treated animals.
Conclusions:
- Solid SMEDDS demonstrated superior capability as budesonide carriers for managing distal colitis.
- The developed BUD-SMEDDS offer a promising approach for localized ulcerative colitis treatment.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:21Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
01:18Drug Delivery: Enteral Route
383
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
383
01:22Drug Delivery: Miscellaneous Routes
328
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
328